BSE · 526445
Indrayani Biotech Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹4 Cr with net profit ₹0 Cr — a 0.49% net margin, versus 1.54% the period before.
Shareholding
As of 2026-06-30
- Promoter32.92%
- Public63.95%
- DII3.13%
25,811 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.96× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Diversified - Medium / Small · ranked #21 of 39 by market cap · medians across 35 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Indiabulls Limited | ₹6,714 Cr | 13.91 | 2.14 | 10.93% | 39.53% |
| GOCL Corporation Limited | ₹2,124 Cr | 7.95 | 0.68 | 8.57% | 3188.09% |
| TTK Healthcare Ltd. | ₹1,509 Cr | 19.7 | 1.36 | 5.89% | 8.32% |
| Sobhagya Merchantile Ltd. | ₹1,309 Cr | 63.86 | 4.98 | 9.36% | 9.25% |
| Andrew Yule & Company Ltd. | ₹1,265 Cr | -70.21 | 3.87 | -5.9% | -14.11% |
| Indo Farm Equipment Ltd. | ₹639 Cr | 25.61 | 1.15 | 4.44% | 5.49% |
| Empire Industries Ltd. | ₹616 Cr | 10.94 | 1.75 | 14.67% | 7.5% |
| Oswal Greentech Limited | ₹495 Cr | 12.77 | 0.21 | 1.49% | -162.11% |
| Kalind Limited | ₹478 Cr | 11.62 | 2.26 | 12.86% | 40.84% |
| Trishakti Industries Limited | ₹410 Cr | 37.73 | 8 | 16.72% | 28.47% |
| Indrayani Biotech Ltd.(this company) | ₹84 Cr | 38.57 | 0.69 | 2.96% | 1.2% |
AI analysis
AI-generated · google/gemini-2.5-flashIndrayani Biotech Ltd. is listed on the Indian markets with an unspecified business. The company has a market capitalization of Rs 61 Cr.
Positives
- None identified.
Negatives
- −Indrayani Biotech Ltd. reported a negative profit margin of -5.25%.
- −The company's Return on Equity (ROE) is negative at -10.2%.
- −The Return on Capital Employed (ROCE) is negative at -1.46%.
- −The debt-to-equity ratio is 1.79, indicating significant debt.
- −Promoter shareholding of 24.56% is pledged as of March 2026.
Financial performance
For the fiscal year ending March 2025, Indrayani Biotech Ltd. reported a revenue of Rs 133.35 Cr and a net loss of Rs -6.1075 Cr. The company's profit margin stood at -5.25%. Over the recent quarters, revenue was Rs 35.01 Cr for December 2025 and Rs 35.95 Cr for September 2025. Net profit was Rs 0.06 Cr for December 2025 and Rs 0.4 Cr for September 2025.
Profitability & returns
Indrayani Biotech Ltd. reported a negative Return on Equity (ROE) of -10.2% and a negative Return on Capital Employed (ROCE) of -1.46%. The company's profit margin for the latest fiscal year was -5.25%.
Balance sheet
The company has a book value per share of Rs 15.96. The debt-to-equity ratio is 1.79, indicating a reliance on debt financing. No dividend yield was reported.
Ownership & pledges
A significant portion of promoter shares, 24.56%, are pledged. Specifically, G Swaminathan, a promoter, has pledged 3,720,000 shares, representing 90.07% of their individual holding.
Regulatory & surveillance
No information regarding regulatory or surveillance measures was provided for Indrayani Biotech Ltd.
Data as of — price: 2026-09-17 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.